Please login to the form below

Not currently logged in
Email:
Password:

Atlas Genetics appoints Jeffery Luber as CEO

Former CEO Dr John Clarkson will move into an executive chairman position

Atlas Genetics has appointed its new chief executive officer in the form of Jeffrey Luber, as he succeeds Dr John Clarkson who transitions into executive chairman.

Luber also joins the company’s board following experience in the life sciences industry and holding multiple leadership roles including CEO of EXACT Sciences.

He said: “I am thrilled to join Atlas Genetics given the power of its platform, the strength of its board and leadership team, and its experience investor syndicate.

“As diagnostic testing increasingly becomes more decentralised, I look forward to working with the team to make Atlas the leading global player in POC testing.”

Prior to his new role at Atlas, Luber most recently led the return to growth and sale of Good Start Genetics to Invitae Corp, producing strategic partnerships with Roche Diagnostics and Amazon.

Dr John Clarkson, founding CEO, Atlas Genetics, said: “Jeff’s proven track record and extensive experience in the commercialisation of in vitro diagnostics will be invaluable as we enter the next, exciting phase of growth aimed at improving the diagnosis and treatment of conditions affecting women and families.”

11th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics